AU2022376087A1 - Method or agent with hdac regulator, for treatment of diabetes and complications - Google Patents

Method or agent with hdac regulator, for treatment of diabetes and complications Download PDF

Info

Publication number
AU2022376087A1
AU2022376087A1 AU2022376087A AU2022376087A AU2022376087A1 AU 2022376087 A1 AU2022376087 A1 AU 2022376087A1 AU 2022376087 A AU2022376087 A AU 2022376087A AU 2022376087 A AU2022376087 A AU 2022376087A AU 2022376087 A1 AU2022376087 A1 AU 2022376087A1
Authority
AU
Australia
Prior art keywords
cells
diabetes mellitus
blood glucose
treatment
hdac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022376087A
Other languages
English (en)
Inventor
Miwako KATAGI
Hideto Kojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biozipcode Inc
Original Assignee
Biozipcode Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biozipcode Inc filed Critical Biozipcode Inc
Publication of AU2022376087A1 publication Critical patent/AU2022376087A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022376087A 2021-10-29 2022-10-27 Method or agent with hdac regulator, for treatment of diabetes and complications Pending AU2022376087A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021177845 2021-10-29
JP2021-177845 2021-10-29
PCT/JP2022/040140 WO2023074794A1 (ja) 2021-10-29 2022-10-27 Ｈｄａｃ調節剤による糖尿病ならびに合併症の治療方法または治療剤

Publications (1)

Publication Number Publication Date
AU2022376087A1 true AU2022376087A1 (en) 2024-06-13

Family

ID=86159956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022376087A Pending AU2022376087A1 (en) 2021-10-29 2022-10-27 Method or agent with hdac regulator, for treatment of diabetes and complications

Country Status (7)

Country Link
EP (1) EP4424327A4 (https=)
JP (1) JPWO2023074794A1 (https=)
KR (1) KR20240093575A (https=)
CN (1) CN118475370A (https=)
AU (1) AU2022376087A1 (https=)
IL (1) IL312393A (https=)
WO (1) WO2023074794A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114828890A (zh) * 2019-10-18 2022-07-29 比奥兹普科德公司 使用了干细胞迁移剂的糖尿病治疗
JP2021177845A (ja) 2020-05-12 2021-11-18 株式会社サンセイアールアンドディ 遊技機
KR20230152099A (ko) * 2021-02-26 2023-11-02 가부시키가이샤 바이오지프코드 당뇨병 및 합병증의 신규 치료, 진단 및 검출을 위한 방법 및 제제

Also Published As

Publication number Publication date
JPWO2023074794A1 (https=) 2023-05-04
EP4424327A4 (en) 2025-12-31
WO2023074794A1 (ja) 2023-05-04
IL312393A (en) 2024-06-01
EP4424327A1 (en) 2024-09-04
CN118475370A (zh) 2024-08-09
KR20240093575A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
Mori et al. Critical roles for the TSC-mTOR pathway in β-cell function
US20130085169A1 (en) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
WO2013152120A2 (en) Compositions and methods for promoting intestinal stem cell function
WO2014153385A2 (en) Methods of treating metabolic disorders
JP2023139101A (ja) 幹細胞遊走剤を使用した糖尿病治療
US20240139129A1 (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
KR101910770B1 (ko) Dscr1-4 를 이용한 제2형 당뇨병 치료제의 스크리닝 방법, 및 제2형 당뇨병 진단 또는 예후 예측용 조성물
EP4424327A1 (en) Method or agent with hdac regulator, for treatment of diabetes and complications
US20150313961A1 (en) Materials and Methods for Regulating Whole Body Glucose Homeostasis
CN117512092A (zh) Pdk1在糖尿病神经元损伤和记忆障碍诊治中的应用
KR20130010479A (ko) 췌장 베타 세포에서 인슐린 분비를 향상시키기 위한 ｐ２ｘ 퓨린성 수용체 효능제의 용도
HK40105070A (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
US20230025003A1 (en) Diabetes therapy targeting abnormal stem cells
Bauer The Impact of Mig6 on Pancreatic Endocrine Cell Fate: Alpha and Beta Cell Mass in Health and Disease
HK40074315A (en) Therapy for diabetes using stem cell migration agent
HK40073790A (en) Diabetes therapy targeting abnormal stem cells
HK40073293A (en) Diabetes therapy targeting abnormal stem cells
HK40073547A (en) Therapy for diabetes using stem cell migration agent
Seelam GLP1R IS AT CELL NEGATIVE COSTIMULATORY MOLECULE
JP2020513232A (ja) 糖代謝異常の検出方法と予防及び治療
Vigorelli CD34+ stem cells and epigenetic memory: key players and pharmacological targets in diabetic cardiovascular complication.
US20200405773A1 (en) Promoting and protecting functional beta cell mass by syntaxin 4 enrichment
Singh Hypothalamic Regulation of the Pancreatic Islet of Langerhans
CN112933097A (zh) 医药组合物用于制备促发炎细胞介素抑制剂的用途
Hao et al. (5R)-5-Hydroxytriptolide Alleviate Inflammatory Muscle Injury in a Murine Experimental Autoimmune Myositis